IsoPlexis’ Single-Cell Proteomics Tackles Vaccine Development: Roundtable Discussion from Leading Infectious Disease Researchers

Strategies for Overcoming Challenges in Infectious Disease Research & Vaccine Development with Functional Phenotyping

GEN News recently held a discussion with a group of leading infectious disease and vaccine researchers to discuss their expert views and strategies on infectious disease research and vaccine development. With vaccine development, protective immune monitoring, infectious disease research, and toxicity, there are several common challenges including developing vaccines to create protective T cell response, cellular immune monitoring for protective response early in patients, and cellular prediction and cytokine level monitoring for toxicities related to cytokine storms. This discussion highlights strategies that other researchers can adopt to aid their own research and expands the conversation surrounding infectious diseases.

Dr. Moriya Tsuji of Aaron Diamond AIDS Research Center & Columbia University, Dr. Stanley Perlman of University of Iowa, Dr. Rong Fan of Yale, Dr. Tian Wang of UTMB, and Dr. James R. Heath of Institute for Systems Biology and UCLA joined us in a virtual discussion for key insights into tackling common research and development issues in this space.

The topics covered in this roundtable are:

  • How does understanding and detecting the immune response and function affect developing therapies and vaccines for infectious diseases? How do single-cell tools play a role?
  • What models are available today to look at the innate and adaptive immune responses in relation to infectious diseases and cytokine storms?
  • What are some challenges in pre-clinical vaccine and therapeutic development that can be overcome by having potency tools and better ways to characterize human immune response? Which cellular analysis tools will reveal this potent response?
  • What role do you think assessing and understanding a proteomic cytokine response from immune cells and more systematically in bulk will play in developing better vaccines and therapies for diseases, such as COVID-19?

Access the roundtable here to read the complete discussion.

Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.